Objective IgA nephropathy (IgAN) is widely regarded as a slowly progressive disease. However, a minor population of patients present with a rapidly progressive form of glomerulonephritis (RPGN). Methods We studied 25 cases of IgAN who presented with RPGN. The laboratory data, histology, and five-year prognosis after diagnostic renal biopsy were evaluated. We compared the data of these patients with those of 495 patients with the non-RPGN type. In addition, we divided the patients with the RPGN type of IgAN into a group with reduced renal function and a group with maintained renal function, and compared the data between the two groups. Results In the 'RPGN type', the serum creatinine levels and a 24-hour urinary protein excretion were significantly higher than in the non-RPGN type. Histological examinations showed that the rates of endocapillary hypercellularity and tubular atrophy/interstitial fibrosis were significantly higher in the patients with the RPGN type. In the comparison between the groups with reduced and maintained renal functions, the former group exhibited higher levels of proteinuria, serum creatinine and crescent formation than the latter group. Conclusion The RPGN type of IgAN was significantly worse in terms of the renal survival rate at five years than the non-RPGN type. Intensive and active treatments are necessary for this minor population, according to the guideline for the management of RPGN.
Introduction
IgA nephropathy (IgAN) is the most common cause of glomerulonephritis worldwide, and is also currently known as one of the most important causes of end-stage renal disease [ESRD (1, 2) ]. It is generally diagnosed by a chance detection of hematuria and/or proteinuria in routine medical examinations. Rarely, patients present with nephrotic syndrome (3, 4) . The prognosis is highly variable, with some patients showing rapid progression to ESRD. The factors influencing the renal survival prognosis, as well as the precise mechanisms underlying the rapid progression of the disease, remain elusive. The purpose of this study was to conduct a retrospective investigation of the incidence, clinical and pathological characteristics and outcomes of IgAN patients presenting with clinical/histological evidence of rapidly progressive form of glomerulonephritis (RPGN) at diagnosis. the RPGN type IgAN was defined as IgA nephropathy presenting with the rapidly progressive type of glomerulonephritis exhibiting renal failure syndrome with acute or latent hematuria or proteinuria (5, 6) . In order to compare the characteristics of IgAN patients presenting with evidence of RPGN at the time of the initial renal biopsy (25 cases) and those of patients with IgAN of the non-RPGN type (495 cases), the clinical data such as the age and blood pressure, as well as the laboratory data, including the 24-hour urinary protein level [U-prot (g/day)], urinary red blood cell count [which we classified into seven grades as: Grade 0, <1/HPF (high-power field)]; 1, 1-4/HPF; 2, 5-9/HPF; 3, 10-19/HPF; 4, 20-29/HPF; 5, 30-49/HPF; 6, 50-99/HPF and 7, 100</HPF. (%), the serum creatinine (S-Cr, mg/dL), serum albumin (Alb, g/dL), serum total cholesterol level (TC, mg/dL), serum MPO-anti-neutrophil cytoplasmic antibody(ANCA), PR3-ANCA and the estimated glomerular filtration rate [eGFR (mL/min) as calculated by the Modification of Diet in Renal Disease (MDRD)] were also evaluated in the patients with and without evidence of RPGN at the time of diagnosis. All patients had negative serological results for a panel of autoantibodies; including antinuclear, anti-double-stranded DNA and anti-cryoglobulin antibodies. Patients were examined at baseline, that is, at the time of the diagnostic renal biopsy, and at one, two, three, four and five years after the diagnosis. In addition, we divided the RPGN patients into two groups; a group with reduced renal function [reduction of the eGFR (mL/min) by over 30% or progression to end-stage renal disease, including the need for hemodialysis initiation during the five-year study period] and the group with maintained renal function [reduction of the eGFR (mL/min) by less than 30% during the five-year study period]. The patient age and blood pressure (mmHg) and also the laboratory data, including the 24hour urinary protein excretion level [U-prot (g/day)], urinary red blood cell count [U-RBC/HPF (high-power field)], serum creatinine (S-Cr, mg/dL), serum albumin (Alb, g/dL), serum total cholesterol (TC, mg/dL) and the eGFR (mL/ min) were examined and compared between the two groups.
This cohort study was conducted in accordance with the Declaration of Helsinki. The Research Ethics Board of Tokyo Women's Medical University approved the study protocol. All patients gave written informed consent for their participation.
Histological examination
The specimens were fixed with 10% phosphate-buffered formalin (pH 7.2), embedded in paraffin, and cut into 2-μmthick sections. The sections were stained with Hematoxylin and Eosin staining, periodic-acid Schiff (PAS), silver methenamine and Masson trichrome for the light microscopic analyses.
Two independent observers without knowledge of the clinical data scored the findings semi-quantitatively. The histological findings, such as mesangial and endothelial hypercellulality, segmental glomerular sclerosis and tubular atro-phy/interstitial fibrosis were graded according to the Oxford classification (7) . Biopsies containing <8 glomeruli were excluded from the analysis based on the Oxford classification.
Statistical analysis
The data were expressed as the means ± SD except nonparametric data. The significance of differences between groups was examined using Student's t-test for non-paired samples and by the chi-squared test.
The evolution of the clinical parameters was analyzed in both groups by a repeated-measures analysis of variance (ANOVA). When differences were observed, the values were compared with the baseline values using a paired-sample ttest. Values of p<0.05 were considered to denote statistical significance. All statistical analyses were performed using the JMP 8 software program (SAS Institute, Cary, NC, USA).
Results
Twenty-five patients with IgAN were diagnosed to have the RPGN type of the disease among a total of 520 patients diagnosed to have IgAN by a renal biopsy (25/520 patients, 4.8%). The flow chart of the study is shown in Fig. 1 . The 25 RPGN patients consisted of 14 men and 11 women, with a mean age of 37.2±10.0 years (mean age of the non-RPGN type; 33.7±11.8 years). The average interval from the onset of symptoms to the diagnosis of RPGN was 84.8±65.9 days (vs. non-RPGN group, 1,247.9±1,086.0 days). None of patients showed positive test results for ANCAs. In the RPGN type patients, six patients started hemodialysis during the five-year observation period (6/25 patients, 24%); the average interval until the initiation of hemodialysis was 4.85±0.5 years. In the non-RPGN type group, 15 patients needed hemodialysis during the study period (15/495 patients, 3.0%). The renal survival rates are shown in Fig. 2 . The renal survival rate at five years was significantly worse in the group with the RPGN type IgAN than in the group with the non-RPGN type.
The clinical data of the two groups at the time of diagnosis and at the five-year follow-up examination are shown in Table 1 . A comparison revealed significant differences in the 1.5 g/day at the time of diagnosis to 1.3±0.7 g/day at five years (p=0.03). The treatments are shown in Table 1 . In the group with the RPGN type IgAN, all of the patients were treated with steroids and antiplatelet drugs. Oral prednisolone treatment was indicated based on the following criteria: (1) proteinuria; >1.0 g/day or (2) severe inflammatory activity, such as the presence of cellular and/or fibrocellular crescents, mesangial interposition with mononuclear cell infiltration and severe interstitial inflammatory cell infiltration. The patients were initially treated with prednisolone at a dose of 0.8 mg/ kg per day for the first four weeks, and the dose was gradually reduced to 20-30 mg on alternate days for the subsequent year. When the treatment was effective, alternate-day prednisolone administration at 10-15 mg was continued during the next follow-up period. When the treatment was not effective, the dose was reduced until discontinuation. An anti-platelet agent (dipyridamole or dilazep) was administered in combination with prednisolone in the patients. Only two patients received steroid pulse therapy and tonsillectomy, and only one patient received immunosuppressant drug therapy (intravenous cyclophosphamide pulse (CyP)). The percentage of patients receiving steroids and antiplatelet drugs was significantly higher in the RPGN patient group (p=0.04). The percentage of patients receiving Ca blockers was also significantly higher in the group with the RPGN type IgAN than in that with the non-RPGN type of the disease (p=0.0001).
Biopsies containing <8 glomeruli were excluded from the analysis according to the Oxford classification. Thus, 413 among the 495 patients in the non-RPGN type group were compared with the RPGN type group. The results of the histological examinations based on the Oxford classification in the two groups are shown in The results of the histological examinations in the two groups are shown in Table 4 . There were no significant differences in the histological examination between the two groups ( 
Discussion
IgAN is currently to be one of the important causes of ESRD (1, 2) . Approximately, 25 to 30% of patients require renal replacement therapy within 20 to 25 years (3, 4) . In addition, a minority of patients present with clinical/histo- Crescentic glomerulonephritis is an uncommon finding in the native kidneys, and in about 3 to 5% of the cases of IgAN, crescents are seen in more than 50% of the glomeruli (8) (9) (10) (11) . Accumulating data suggest that the renal survival in cases of crescentic IgAN is only 50% at one year, and 20% at five years (12) . On the other hand, according to one report, patients with >25% crescents at the initial biopsy showed a -50% renal survival after four years (13) . These reports showed that patients with the RPGN type or crescentic glomerulonephritis showed significantly worse outcomes than those without.
Crescent formation involving more than 50% of the glomeruli is referred to as diffuse crescentic IgAN (DCIgAN) or rapidly progressive glomerulonephritis (14) . D'Amico et al. found that, in idiopathic IgAN patients showing glomerular crescent formation, the necrotizing capillary lesions were similar, in terms of the histopathological and immunohistochemical features, to those in patients with Henoch-Schonlein purpura and ANCA-positive systemic vasculitis (12) . Tomino et al. (15) reported that in patients with IgAN with a poor prognosis, severe, diffuse mesangial cell proliferation and increased matrix degradation, glomerulosclerosis, crescent formation and/or adhesion to Bowman's capsule was observed in more than 30% of all biopsied glomeruli. When sclerotic sites comprised more than 50% of the glomeruli, the sclerosis rate was the most important of these indices in terms of the prognosis. In this study, the percentage of glomerular obsolescence was 30.7% and that of crescent formation was 33.0%, and pathological changes of the glomerulus were noted in 63.4% of cases ( Table 2 -2). The percentages of glomerular obsolescence and crescent formation exceeded more than 50%, however, the main con-stituent was acute damage, including crescent formation, and glomerular obsolescence above 50% was not observed. The treatment for acute lesions in the glomerulus, prednisolone, was probably more effective than it would be for chronic lesions, such as glomerular obsolescence. That might explain the better five-year renal survival rate (76%) in this study, than that in a previous report (15) .
Reich et al. revealed that the rate of GFR decline was significantly lower in patients with proteinuria <1 g/day than in those with proteinuria >1 g/day, and that proteinuria was therefore the most important predictor of the rate of GFR decline (16) . In this study, more severe proteinuria was seen in the reduced renal function group than in the maintained renal function group of RPGN patients at the time of diagnosis.
Many studies have reported that the renal survival is much poorer in patients with the RPGN type of IgAN than the general IgAN population. However, a number of optimistic case series have recently been published indicating good preservation of the renal function obtained with the use of treatment regimens similar to those recommended for renal vasculitis; high-dose corticosteroids and cyclophosphamide, and in some cases, plasma exchange (6, 17 ). Anecdotal reports claim variable degrees of benefit from plasma exchange in patients with active, severe IgAN (18, 19) . However, there have still not been any RCTs of these treatments in patients with crescentic IgAN, and the response to treatment is not uniform. It is not uncommon to see crescentic changes on a background of chronic glomerular and tubulointerstitial injury; such chronicity usually is predictive of a poor response to intensive immunosuppressive treatment. Tang et al. reported that, of 21 patients who were administered pulse methylprednisolone therapy and/or monthly intravenous cyclophosphamide therapy, 15 were followed up for more than six months, and 66.7% of these patients had life-sustaining renal function (20) . These results suggest the usefulness of intensive immunosuppressant treatment for improving the renal function in patients with RPGN type IgAN.
In this study, 25 patients with the RPGN type were treated with oral prednisolone (0.5-0.8 mg/kg/day or twice day) and antiplatelet drugs. Several centers have recently performed tonsillectomy + steroid pulse therapy, even in milder cases. At our center, much better outcomes in terms of the renal survival rate have recently been reported. However, in the patients with the RPGN type of IgAN, the rate of hemodialysis initiation within five years was 24.0%.
The RPGN type showed a significantly higher level of tubular atrophy/interstitial fibrosis, as shown in Table 2 -1. Alexopolos et al. found that 80% of idiopathic RPGN patients showed tubular atrophy/interstitial fibrosis, which was the same as our results. In addition, idiopathic RPGN patients and non-responders to treatment showed significantly higher levels of tubular atrophy and interstitial fibrosis (21) .
As shown in Table 4 -2, the percentage of glomeruli showing cellular and fibrocellular crescent formation was significantly higher in the renal dysfunction group than in the maintained renal function group in the present study. This indicates that, in patients with the RPGN type of IgAN, more intensive and active treatment is necessary, according to the guideline for the management of RPGN (such as the treatment used for ANCA-associated vasculitis or systemic vasculitis). However, our study has some limitations. First, the study design was a retrospective observation, and the sample size of the RPGN type patients was small. We have shown that the RPGN type patients had a significantly worse renal survival rate, and therefore, intensive and active treatment might be necessary. Previous reports also suggested that intensive immunosuppressant treatment (such as high-dose corticosteroids and cyclophosphamide, and in some cases, plasma exchange) improved the renal function in patients with RPGN type IgAN. However, in this study, only two patients were treated with tonsillectomy (with steroid pulse), and one patient was treated with an immunosuppressive drug (cyclophosphamide). Therefore, our study could not reach a clear conclusion that intensive treatment contributes to a better outcome in terms of the renal survival rate. In addition, the number of RPGN type patients was only 25, with the reduced renal function group (n=11) and maintained renal function group (n=14) being still smaller. No significant differences were seen with regard to treatment between the two groups.
Additional investigations with a longer follow-up period are required to provide a more precise evaluation of the long-term prognosis of IgAN patients presenting with clinical/histological evidence of RPGN at diagnosis.
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